Wire · opportunities
FDA authorizes Abbott's wearable to monitor ketone and glucose in diabetes patients
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 26 August 2026 · Fusion42 review
The U.S. FDA authorized Abbott Laboratories' Libre Duo 10 Day device, the first to continuously monitor both ketone and glucose levels in diabetes patients, enabling real-time alerts to prevent diabetic ketoacidosis emergencies.
This Wire brief sits within Fusion42's coverage of Digital Health, and 7 sources have reported it between 25 Aug 2026 and 27 Aug 2026.
◆ ◆ The Wire takeaway
You must update your diabetes care offering as continuous ketone monitoring becomes possible in a single device, unlocking new prevention capabilities before emergencies escalate. This FDA clearance opens partnerships with pump makers that you can now pursue to embed in insulin delivery systems.
◆ Coverage
7 sources · first reported 25 Aug 2026 · latest 27 Aug 2026
◆ Related on Wire
◆ Topics